ZERBAXA POWDER FOR SOLUTION

Land: Kanada

Språk: engelska

Källa: Health Canada

Aktiva substanser:

CEFTOLOZANE (CEFTOLOZANE SULFATE); TAZOBACTAM (TAZOBACTAM SODIUM)

Tillgänglig från:

MERCK CANADA INC

ATC-kod:

J01DI54

INN (International namn):

CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR

Dos:

1G; 0.5G

Läkemedelsform:

POWDER FOR SOLUTION

Sammansättning:

CEFTOLOZANE (CEFTOLOZANE SULFATE) 1G; TAZOBACTAM (TAZOBACTAM SODIUM) 0.5G

Administreringssätt:

INTRAVENOUS

Enheter i paketet:

11.4ML (RECONST.) (1.5G)

Receptbelagda typ:

Prescription

Terapiområde:

THIRD GENERATION CEPHALOSPORINS

Produktsammanfattning:

Active ingredient group (AIG) number: 0257450001; AHFS:

Bemyndigande status:

APPROVED

Tillstånd datum:

2015-09-30

Produktens egenskaper

_ZERBAXA_
_®_
_ (ceftolozane and tazobactam) _
_Page 1 of 41_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ZERBAXA
®
Ceftolozane and Tazobactam powder for injection
1.5 gram (g) per vial
Containing ceftolozane 1 g (as ceftolozane sulfate) and tazobactam 0.5
g (as tazobactam sodium)
Cephalosporin and Beta-lactamase Inhibitor
antibacterial for systemic use
MERCK CANADA INC.
DATE OF PREPARATION:
16750 route Transcanadienne
October 7, 2020
Kirkland, QC
Canada H9H 4M7
www.merck.ca
SUBMISSION CONTROL NO: 238477
_ _
_ZERBAXA_
®
_ (ceftolozane and tazobactam) _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL